DMBSS-A Randomized Trial of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM

NCT ID: NCT01989988

Last Updated: 2013-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators would like to conduct a randomized clinical trial to compare the efficacy of diabetes treatment between different gastric bypass procedures involving type 2 diabetics patients with BMI from 27.5 to 35 kg/m2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators would like to conduct a randomized clinical trial to compare the efficacy of diabetes treatment between different gastric bypass procedures involving type 2 diabetics patients with BMI from 27.5 to 35 kg/m2. This program will determine the relative effectiveness among LMGB 、RYGB and SADJB .The primary end point including HbA1C\<6.0%, LDL-C\<100mg/dl and SBP\<130mmHg at one year after surgery. Through this study, the investigators may understand which gastric bypass is the best for type 2 diabetic's treatment. The investigators also hope some new treatment modulation may be developed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Type 2 in Obese

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Type 2 Diabetes Mellitus (T2DM) Obesity Laparoscopic gastric bypass Duodenum exclusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LRYGB

20 subjects Randomized will undergo LRYGB surgery

Group Type ACTIVE_COMPARATOR

LRYGB

Intervention Type PROCEDURE

SADJB

20 subjects will undergo SADJB surgery

Group Type ACTIVE_COMPARATOR

SADJB

Intervention Type PROCEDURE

LMGB

20 subjects will undergo LMGB surgery

Group Type ACTIVE_COMPARATOR

LMGB

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LMGB

Intervention Type PROCEDURE

LRYGB

Intervention Type PROCEDURE

SADJB

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 20 to 67 years
* Diagnosed with T2DM at least 6 months prior to enrollment, under the active care of a doctor for at least the six months prior to enrollment, HbA1c ≥ 7.5 %
* Body Mass Index (BMI) ≥ 27.5 kg/m 2 and ≤ 34.9 kg/m 2
* Willingness to accept random assignment to either treatment group.
* Willingness to comply with the follow-up protocol
* Written informed consent.

Exclusion Criteria

* Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.
* Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease.
* Cardiac stress test indicating that surgery would not be safe.
* Pulmonary embolus or thrombophlebitis in the past six months
* Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years
* Serum creatinine ≥ 1.5 mg/dl
* History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection
* Previous organ transplantation.
* History of alcohol or drug dependency
* Current participation in a conflicting research protocol.
Minimum Eligible Age

20 Years

Maximum Eligible Age

67 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Min-Sheng General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

WEI-CHENG YAO

Department of Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wei-Jei Lee, M.D., PH.D

Role: STUDY_CHAIR

Min-Sheng General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Min-Sheng General Hospital

Taoyuan, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MSIRB2013003

Identifier Type: OTHER

Identifier Source: secondary_id

MSIRB2013003

Identifier Type: -

Identifier Source: org_study_id